Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.62 |
| ▸ | SRC | P12931 | 5/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | BCR | P11274 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545984 | 0.94 | ABL1 (0.55) | ABL1SRCBRAFCDK1CDK2 | |
| SCHEMBL544927 | 0.92 | ABL1 (0.53) | ABL1SRCKITBRAFEGFR | |
| SCHEMBL14493361 | 0.88 | ABL1 (0.54) | ABL1SRCBRAFEGFRCDK1 | |
| SCHEMBL545648 | 0.87 | ABL1 (0.58) | ABL1SRCKITBRAFEGFR | |
| SCHEMBL10301389 | 0.86 | SRC (0.60) | ABL1SRCKITCDK1CDK2 | |
| SCHEMBL546218 | 0.86 | BRAF (0.48) | ABL1SRCBRAFBCRMKNK1 | |
| SCHEMBL546349 | 0.85 | ABL1 (0.45) | ABL1SRCBRAFBCRMKNK1 | |
| SCHEMBL546771 | 0.82 | BRAF (0.57) | ABL1SRCKITBRAFEGFR | |
| SCHEMBL545443 | 0.81 | KDR (0.53) | ABL1SRCKITBRAFEGFR | |
| SCHEMBL546225 | 0.80 | BRAF (0.62) | ABL1SRCBRAFCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | ABL1 37/4885SRC 180/4885KIT 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.